P. 1


|Views: 2|Likes:
Published by Mohammed Raafat

More info:

Published by: Mohammed Raafat on Apr 23, 2014
Copyright:Traditional Copyright: All rights reserved


Read on Scribd mobile: iPhone, iPad and Android.
download as PDF, TXT or read online from Scribd
See more
See less





Seminar on Vinpocetine

Introduction The loss of cognitive functioning has become a major health concern due to the high number of individuals experiencing dementia, memory loss and other such difficulties, and also due to the lack of effective existing medical treatment. It is often passed off as a natural part of aging, but you will see that nutritional and botanical support are proven to enhance cognitive function and very importantly, help reverse and prevent cognitive dysfunction. We will be discussing the botanical extract Vinpocetine. Background At birth the human brain contains as many as one hundred billion nerve cells. From then on there is a continuous process of decline. Brain weight decreases gradually over time - about 10% over a normal life span, due to neuron death. Different parts of the brain lose neurons at different rates. In most brain stem regions below the cerebral cortex (the area responsible for automatic unlearned activity (breathing, heart pumping, blinking, etc.), there is little or no cell loss with advancing age. In comparison, the cerebral cortex, which is responsible for thinking and memory, loses up to 50,000 neurons a day. Definition/Description Vinpocetine is a derivative of Vincamine, which is an alkaloid of the common periwinkle plant (Vinca minor). It selectively dilates the arteries and capillaries in the head area, which improves circulation to the brain, thus alleviating cerebral insufficiency. Ongoing research around the world indicates that it may help improve memory, learning ability, insomnia, hearing, eyesight, and effects of menopause, and increase tolerance to damage caused by hypoxia (lack of oxygen, such as occurs with a stroke or heart attack). Vinpocetine is often used for the treatment of cerebral circulatory disorders such as memory problems, acute stroke, aphasia (loss of the power of expression), apraxia (inability to coordinate movements), motor disorders, dizziness, tinnitus and other inner-ear problems, and headache. Vinpocetine is also used to treat acute or chronic

(Kiss. 3. the improvement of blood flow to the brain. Increases blood flow.ophthalmological diseases of various origins. In particular. Miyata) 5 ways Vinpocetine increases brain metabolism: 1. It is important to note that Vinpocetine is not only a cerebral vasodilator. (Shibuya) . (Milusheva. (Luciana) Acetylcholine: Associated with memory and memory loss. Increases the rate at which brain cells produce ATP (which is a cell molecule that creates energy). Vinpocetine increases levels of neurotransmitters involved in memory function: Noradrenaline: Found principally in neurons of the locus coeruleus (LC) area of the brain. appetite disorders. Many studies have been performed on cerebral metabolism. Dopamine: Associated with reward-seeking behaviour and spatial working memory tasks. Low levels have been associated with depression. Matsukawa) Serotonine: Associated with mood regulation and sleep. etc. addiction disorders. Speeds up the use of oxygen in the brain. 5. 2. with visual acuity improving in 70% of the subjects. but that its principal action is a beneficial effect on the cerebral metabolism. sleep disorders. Speeds up the use of glucose in the brain. How Vinpocetine Effects the Brain Vinpocetine improves four different and fundamental aspects of cerebral metabolism. Regulates Sodium/ Potassium channels 4. as it is immediate and practical to measure.

Vinpocetine has several different effects that have various important effects on cognitive function. This treatment with vinpocetine was also associated with improvements in short-term memory processes. on induced impairment of memory were studied in eight normal volunteers. alertness and information processing associated with aging.degeneration is slightly faster in men compared to women. (Vamposi) Vinpocetine increases ATP synthesis (Nicholson) and is especially beneficial for individuals whose dementia may be caused by vascular insufficiency. (Bhatti) . vinpocetine improves overall cerebral efficiency resulting in brain cells that can better retain information so we can remember more. Animal studies conducted in Hungary by Gaal. anxiety. healthy volunteers showed incredible short-term memory improvement one hour after taking 40 mg. sleep-wake cycle. show that Vinpocetine increases the firing ability on LC and therefore improve cognition and related cognitive-enhancing characteristics. et al. This decline plays a significant role in the reduction of concentration. Of vinpocetine. normal. (Subhan) The effects of pre-treatment with vinpocetine 40 mg. The final result of the joint actions is the improvement of overall cognitive function. (Biro) Short term memory and learning In one double-blind crossover study. stress and autonomic control. These result in benefits for: Dementia Both animal and human studies show Vinpocetine is able to restore impaired brain energy metabolism. These are involved in regulating learning and memory. LC neurons decline in number with age . By acting in these five ways.Vinpocetine stimulates Locus Coeruleus (LC) neurons: LC Neurons are the noradrenaline nerve clusters throughout the cerebral cortex of the brain.

000 patients. Stroke Vinpocetine also has properties as an anti-platelet aggregation blood thinner. as well as its general action of vinpocetine in the brain.Studies have also shown memory improvement in the elderly. Other Applications Tinnitus and Other Hearing Problems Hearing dysfunction such as tinnitus (ringing in the ears) and progressive sensorineural hearing loss (PSNHL) are commonly caused by cerebral vascular factors. on a total of over 20. such as macular degeneration. Matsnev) Vascular problems of the inner ear such as tinnitus can benefit from vinpocetine as it has been used for the hearing loss of senile or toxic origin and labyrinthic vertigos (dizziness). Vinpocetine selectively dilates the cerebral artery. have studied its specific action on memory. and other vision disorders of vascular origin. Ribari. certain problems related to glaucoma. This inhibits blood clotting and aids in the normalization of blood flow. Over more than 100 clinical trials have been performed with vinpocetine. (Taiji. which can be useful for treatment of stroke and aid in the reflow of blood to these areas. Vision Problems Vinpocetine has been used for blood flow problems of the choroid and retina. . The increase of blood viscosity and/or increase of rigidity of the red blood cells have been reported by several authors as a contributing factor. The majority of these studies were performed with elderly patients. and some of them. (Ravecca) Tinnitus is one of the problems for which vinpocetine has been most studied and results are very promising. which are all inner ear disorders of vascular origin. Konopke. Ordogh.

impairing microcirculation. Histamine-stimulated gastric acid secretion was partially inhibited by vinpocetine. The highest protective activity was observed when vinpocetine was given 30 minutes before ethanol. which may be triggered by a high fat diet. The effectiveness of vinpocetine to prevent gastric mucosal damage induced by several agents and its antisecretory effect was studied in rats. after vinpocetine administration of 15 mg. In the Japanese study. researchers noted vinpocetine’s inhibition of platelet aggregation (clotting). Blood levels of alkaline phosphatase and bone osteocalcin tended to decrease after treatment with vinpocetine. Vinpocetine proved to inhibit the development of gastric lesions induced by 96% ethanol in a dose-dependent way. and stress hormones.In a study with 100 patients suffering from poor blood circulation to the eye. (Kaham) Stomach Ulcers Vinpocetine may help ward off stomach ulcers. (Nosalova) Kidney Stones Japanese researchers at the Wakayama Medical College showed that vinpocetine supplementation is able to remove tumoral calcinosis in kidney dialysis patients with renal (kidney) failure. among other factors./day for 3-12 months. researchers suspected that it may be of benefit to remove undesirable mineral deposits elsewhere in the body as well. . The microvessels that feed neurons in the brain and retina are smaller in diameter than a single red blood cell and are easily “clogged” by clumps of platelets. and its effect was still significant when administered 120 minutes before ethanol exposure. kidney dialysis patients with X-ray evidence of kidney stones (tumoral calcinosis) experienced complete elimination of calcinosis in all eight cases. As other studies have shown that vinpocetine can effectively scavenge undesirable minerals and/or metals in the soft tissues of rabbits with artificially induced arteriosclerosis. This provides another mechanism of action for vinpocetine’s ability to enhance cerebral blood flow-inhibition of unnecessary platelet aggregation. The also study suggested the involvement of a prostaglandin-mediated mechanism against acetic acid-induced damage. magnesium deficiency.

The mechanism of action of Vinpocetine is the same but with the advantage of no side effects. The most common ingredient used against hair loss is Mynoxidil. some people taking vinpocetine orally. (Miyata) Hair Loss Due to the improvement of peripheral microcirculation in microvessels of the head. (Covex) Studies are being performed with hydroalcoholic solutions of vinpocetine.Vinpocetine had this remarkable effect without any side effects during treatment. (Covex) . have reported are more vigorous hair condition. used as hair lotions for the hair skin. which is a strong peripheral vasodilator with adverse side effects. stating they no longer feel strong hair loss.

This means there is actually a reduction in the effort of the heart. Improvements in cerebral disorders and in hearing and vision problems may last only as long as it is being taken on a regular basis. concentration. and alertness were the first symptoms to be relieved by use of Ginkgo Biloba. systemic circulation and actually vascular resistance actually slightly decreases. it is increasing the heart rate and how does this affect the heart? A: Vinpocetine selectively increases the cerebral fraction of cardiac output. (Solti) Q: How long does it take to see any results when taking Vinpocetine? A: While some Vinpocetine users notice cognitive improvements after a single dose or within the first few days. others may not see major improvement in medical situations for weeks or months. . It does not effect blood pressure. Q: If Vinpocetine increases blood flow to the brain. Studies involving 1. (Soholm) It’s active terpenes are antagonists of PAF (Platelet activating factor) which has negative neural effects.many individuals experiencing benefit in just a few days.also vinpocetine’s effects are much quicker .200 patients showed that memory. A minimum of 4 to 6 weeks were needed before a pronounced effect could be expected. with tinnitus and dizziness improving somewhat later. Vinpocetine seems to have a much broader mode of action and can therefore assist a wider variety of individuals .Commonly Asked Questions about Vinpocetine Q: How is Vinpocetine different from Ginkgo Biloba? A: Ginkgo’s main effects on cerebral vascular functions are mainly due to its vasoactive and antioxidant effects.

Vinpocetine is normally taken orally. Q: Can Vinpocetine be used with other supplements? A: Vinpocetine works great taken alone. If taken with other cerebro-active substances. It may interfere with sleep so I would not suggest taking a high dosage in the evening. Q: What happens if you take too much? A: The most commonly reported feeling is a sensation of feeling over-revved. These will discontinue if you reduce your dosage or stop taking it. It is best to take Vinpocetine with food to avoid stomach upset. per day. Other mild side effects reports include dry mouth..Q: What is the suggested dosage? A: The usual therapeutic dose for Vinpocetine for humans is 15-30 mg. 5-10 mg. . rapid heartbeat. low blood pressure and rash/or hives. Vinpocetine may enhance their effects thus possibly reducing their dosage requirements. two or three times daily. Q: Are there any side effects with Vinpocetine? A: Vinpocetine is very safe for long-term use. and yet also works well when combined with other memory enhancing nutrients.

U. Chinoin Co. 28.314(1-2):69-73. Keim KL. Wood LM. Molnar P. Vincamine and vincanol are potent blockers of voltage-gated Na+ channels. Vascular cognitive impairment: a new approach to vascular dementia. Budapest. Gelpke LW. Status of the nonspecific systems of the brain in initial manifestations of insufficiency of cerebral blood supply and circulatory encephalopathy. Pharmacol Biochem Behav 1986 Apr. Moscow. London. Laboratory of CNS Pharmacology. Molnar P. Medical Sciences. Repetti SJ. K. Nootropic agent vinpocetine blocks delayed rectified potassium currents more strongly than high-threshold calcium currents. DeNoble V. Human Psychopharmacology Research Unit. 1992. Solntseva E. Chemical Works of Gedeon Richter Ltd. Vinpocetine effects on cognitive impairments produced by flunitrazepam. Eur J Pharmacol 1990 Oct 23. “Protective activity of Ethyl Apovincaminate on ischaemic anoxia of the brain” AF(DR) 1976. [The nootropic agent vinpocetine blocks the delayed rectifier potassium channel more strongly than the high-conductance calcium channel] Zh Vyssh Nerv Deiat Im I P Pavlova 1996 Sep-Oct. .92(1):38-40. Science Research Institute of the Brain. Rudge S. Covex.K. Zh Nevropatol Psikhiatr Im S S Korsakova. Southall. Biro.Bibliography Baldwin D. Biochem Behav 1987 Jan. Madrid. Middlesex. DeNoble VJ. Bowler J. Ealing Mental Health Unit. Spain. Eur J Pharmacol 1996 Oct 24. Tomoskozi Z.Budapest. Bukanova Y. Hungary. Russian Academy. Baillieres Clin Neurol 1995 Aug. Lakics V.28(2):116-20. Int Clin Psychopharmacol 1987 Oct.. Gaal L. The role of serotonine in depression and anxiety. Vinpocetine: nootropic effects on scopolamine-induced and hypoxia.9 Suppl 4:41-5 Bhatti JZ. University of Western Ontario. University of Leeds. Busakov BS. Hungary. Gafurov BG. UK. Bukanova I. Effect of vinpocetine on noradrenergic neurons in rat locus coeruleus.187(3):537-9. Bence JZ.4(2):35776. Hachinski V. Department of Biochemistry.induced retrieval deficits of a step-through passive avoidance response in rats.24(4):1123-8. Vinpocetine enhances retrieval of a step-through passive avoidance response in rats. 1918-20. et al.2(4):325-31..26(1):183-6. Neurosci Behav Physiol 1998 Mar-Apr. Solntseva E. Erdo SA. personal conversation 11/16/99. Int Clin Psychopharmacol 1995 Jan. Canada.. Hindmarch I.46(5):911-6.

Ghelardini C. 1986.. Ogawa M. Richter Gedeon Vegyeszeti Gyar Rt. USA. MD. Farmakologiai Kutato Kozpont. Fornal CA. Altern Medical Rev 1999 Jun. Neurosci Lett 1995 Feb 9. B..Garcia. [Mechanism of action of vinpocetine] Vinpocetine hatasai. 1969-72. 14: 577. Chinoin Co. Nakadate K. Kanzaki. animal models and emerging therapies. Lilly Corporate Center. Taiji.4(3):144-61. 0. H. Kawai N. D. CNS Pharmacology Laboratory. Kidd PM..94(9):4430-4.. Luciana M. .4:281-6. L. et al. Matsukawa M.. Eli Lilly and Company. Dahl D.induced cell death in primary cultures of rat cerebral cortex. 263-279. Ltd..Acta Pharm Hung 1996 Sep.. Collins PF. Nebreda. Phebus LA. L.51:219-44. Sebestyen MG. IN Prog Drug Res 1998. Correspondence address:47 Elm St. Szporny. Department of Psychology.et al. Princeton University. Eugene. Activity of serotonergic neurons in behaving animals. JPN Pharmacol Ter.66(5):213-24. Japan. Budapest. Mental Illness in the Elderly. CA 94530. National Institutes of Health. Space and Enviromental Medicine.. Cereb Cortex 1998 Apr-May. 8(3):218-26. D of Psychology. Indianapolis. NJ. 55. University of Tsukuba. A review of nutrients and botanicals in the integrative management of cognitive dysfunction Contributing Editor. Lakics V. Use of Ethyl Apovincaminate in ophthalmological therapy” AF(DR) 1976. Bodo. Meiri N. Proc Natl Acad Sci U S A 1997 Apr 29.. F. Cohen ML. U of Oregon. Neuropsychopharmacology 1999 Aug.. Ibaraki. Budapest. Galeotti N. (1988) 14. Res. Aviation. “Clinical Study of Vinpocetine in the treatment of vertigo. Neurosci Lett 1997 Jul 11. J.1 potassium channel expression impairs associative memory in mouse and rat. Karpati E. 9. Opposing roles for dopamine and serotonin in the modulation of human spatial working memory functions. “Experimental Assessment of Selected Antimotion Drugs”. Reversible ntisense inhibition of Shakerlike Kv1.185(2):127-30.21(2 Suppl):9S15S. E. Drug Dev.Vinpocetine is a highly potent neuroprotectant against veratridine. Jacobs BL. Kaham. Serotonine in migraine: theories. Lilly Research Laboratories. Maeshima T. On the possible role of central monominergic systems in the central nervous systems actions of vinpocetine.. Hungary. hatasmechanizmusa. Johnson KW.. OlahM. Alternative Medicine Review. Bethesda. 1984. Tesco G. 1994. 28. Kiss.”.230(1):13-6 Matsnev. Institute of Basic Medical Sciences... Erdo SL. El Cerrito. Serotonin and acetylcholine are crucial to maintain hippocampal synapses and memory acquisition in rats. Ichitani Y. Kiss B. A. Perlado.

on isolated blood vessels: cerebroarterial selectivity.147-59. Arzneimittelforschung 1993 Sep. on cerebral vascular resistance evaluated by the Doppler ultrasonic technique in patients with cerebrovascular diseases. Angiology 1995 Jan. Chinoin Co. et al.39(4):569-78. 101. PA Neuropsychopharmacology 1998 Jun. 1978 .. Goteborg University. Brain Res.1:16-9. Moldvai I. The effect of a cerebral vasodilator. Research Center. Yamaura H. Miyata N. Part 84. Srossy. B.related impairment evidence in electroencephalograph.. Tanaka M. Therapia Hungarica. Institute of Experimental Pharmacology. B. on age... Szporny. D. Imagawa Y. Araki H. Karpati E.46(1): 53-8. Life Science. DeKosky ST. Psychopharm. Temesvari-Major E. Okuyama S. Saitama. 26.25(7): 1311-20 Ordogh.330(6):190-8. Otomo S. Gen Pharmacol 1994 Nov. Vinpocetine is as potent as phenytoin to block voltage-gated Na+ channels in rat cortical neurons.. 1997 Jun. late-life depression. caudate spindle.Effects of VA-045. Protective action of vinpocetine against experimentally induced gastric damage in rats. Szantay C. and Alzheimer’s disease: the emerging role of functional imaging.Meltzer CC. Smith G. Sperlagh. 1985. Pollock BG. Ogawa S. Kawashima K. Milusheva. 24. (1990). Molnar P. Nicholson. Szantay C Jr. Perfilieva E.. a novel apovincaminic acid derivative. Orwar O. Slovak Academy of Sciences. Hungary.. Serotonin in aging.et al. Institute of Clinical Neuroscience. Bratislava. Sahlgrenska University Hospital. Toth G.273(3):303-6.. University of Pittsburgh Medical Center.. 369-373. vinpocetine. Nilsson M. Bull. Eur J Pharmacol 1995 Feb 6. Sweden. J Neurobiol 1999 Jun 15.43(9):981-5. Budapest. Tsuchida K. Effects of VA-045.18(6):407-30. Machova J. C. Ltd.. Japan. Nosalova V. Taisho Pharmaceutical Co. Ltd. E. Babulova A. Inhibitory effect of hypoxic condition on acetylcholine release is partly due to the effect of adenosine released from the tissue. et al. B. et al. Alzheimer’s Disease Research Center. Kiss. a novel apovincaminic acid derivative. Muramatsu M. “Therapeutic Action of Cavinton in Hearing Defects of Neurological Origin”. Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Synthesis of vinca alkaloids and related compounds. Kawashima Y. Enriched environment increases neurogenesis in the adult rat dentate gyrus and improves spatial memory. Eriksson P. Sulfonamide derivatives of some vinca alkaloids with cardiovascular activity. L. Erdo SL. CNS Pharmacology Laboratory. Johansson U. a passive avoidance task and cerebral blood flow in rats. . Miyazaki M. Hashimoto-Kitsukawa S.

T. Stefani MR. Helkala EL. Res. 1999. Sinclair AJ.18(4):317-21.” Arzneim. Soholm B. 1945-47. Clinical improvement of memory and other cognitive functions by Ginkgo Biloba: review of relevant literature.16(3):419-24. Igaku No Ayumi (1986) 139. Neuroscience. 668-673. University Hospital of Kuopio. Russia. Denmark. et al. K. 217-219. Vereczkey L. Gold PE. 10. ATP-sensitive potassium channel blockade enhances spontaneous alternation performance in the rat: a potential mechanism for glucose. Ross Fiziol Zh Im I M Sechenova 1998 Aug. Stancikova M. UK. et al. Kononen M. Serotonin and acetylcholine release response in the rat hippocampus during a spatial memory task. F. Nicholson GM. Bukanova IuV.T.84(8):741-6.. Vedbaek.-Forsh.Orvisky E. (Drug. Toth.13(12):840-5.. Int J Geriatr Psychiatry 1998 Dec. Altered plasma antioxidant status in subjects with Alzheimer’s disease and vascular dementia. et al. Soininen H.) 1976. et al. Relationship between EEG reactivity and neuropsychological tests in vascular dementia. histological study of brain monomines. Sano-Pharm A/S. Bayer AJ. University of Virginia. Study on the absorption of vinpocetine and apovincaminic acid. Chemical Works of Gedeon Richter Ltd. (3H) Noradrenaline-releasing action of vinpocetine in the isolated main pulmonary artery of the rabbit. Sato. Department of Psychology. Budapest. Partanen J. 1977. High-molecular-weight hyaluronan. Soltes L. Pudleiner P. Moscow.104(8-9):905-12.15(1):54-65. Effects of vinpocetine on experimental brain ischemia. Shibuya.” Curr Ther Res (1985) 37. J Pharm. P. [Cyclic GMP mimicks potentiation effect of the nootropic agent vinpocetine on the high threshold A-current in the mollusk neurons] Institute of Brain Research. T. Otomo. . Ribari. E. Eur J Drug Metab Pharmacokinet 1993 Oct-Dec. Hungary. Finland. 28. Pharmaacol. Selly Oak Hospital. 811-21. Neuroscience 1999. et al. Charlottesville. “Ethyl Apovincaminate in the Treatment of Sensorineural Impairment of hearing. Solntseva EI. J Pharm Biomed Anal 1997 Nov. “Effect of Ethyl Apovincaminate on the cerebral circulation” AF(DR) 1976.a valuable tool in testing the antioxidative activity of amphiphilic drugs stobadine and vinpocetine. Paulo. 3. J Neural Transm 1997..mediated memory enhancement. Birmingham.89(4):1135-43. Adv Ther 1998 JanFeb.93(2):557-63. et al “Comparison of vinpocetine with Ifenprodil Tartrate and Dihyroergotoxine Mesylate treatment and results of long term treatment with vinpocetine. Stancampiano R. Solti. (1986) 38. et al.

Arzneimittelforschung 1990 Jun. Yamada S. Hungary. Nagao Hospital 814-0153 Fukuoka Igaku Zasshi 1998 Nov.8(4):197-204. J Neuroimaging 1998 Oct. Semmelweis University of Medicine. Tohgi H. Shanghai Medical University. Psychopharmacological effects of vinpocetine in normal healthy volunteers. Neuroreport 1998 Jun 1. Gifu.47(1):1-15. Brain Res Bull 1998 Sep 1. Boros I. Turrigiano GG. drowsiness.89(11):303-11. Emri M. Tagawa K.9(8):1849-53. Ueyoshi A.) Van Bockstaele EJ.75(2):963-6.et al.Subhan Z. Ma. et al. Morphological substrates underlying opioid. 1980-84. Okuyama S. Shi NC. Balkay L. Gen Pharmacol 1995 Oct. Budapest.40(6):640-3. Debrecen University Medical School. Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: a PET study. Department of Medical Biochemistry. Chung Kuo Yao Li Hsueh Pao 1997 Sep. Department of Biology. Waltham. Japan. China.28(5):567-71.. Wei Y. Sasaki K. Iwate Medical University. Abbott LF. and a lack of drive as major symptoms] Fukuoka Higher Bain Function Center. Ota K. Inhibitory effects of vinpocetine on sodium current in rat cardiomyocytes. 26(6): 1419-24. B. . Eur J Clin Pharmacol 1985. The neuroprotective drug vinpocetine prevents veratridine-induced [Na+]i and [Ca2+]i rise in synaptosomes. Nozaki Y. Hindmarch I. Japan. epinephrine and gammaaminobutyric acid inhibitory actions in the rat locus coeruleus. Szakall S. School of Basic Medical Sciences. Chiba K. Hungary. Yamaguchi K. Marder E. Zhong CS.18(5):411-5. Effect of vinpocetine on oxygen release of haemoglobin and erythrocyte organic polyphosphate concentrations in patients with vascular dementia of the Binswanger type. Cerebrovascular disorder with memory disturbance. Cellular short-term memory from a slow potassium conductance. appraisal of vinpocetine for the removal of intractable tumoral calcinosis in haemodialysis patients with renal failure.Effects of VA-045 on peripheral and central circulation in anesthetized dogs. Adam-Vizi V. Brandeis University. Department of Neurology. et al (1976) “Comparative study of the effect of Ethyl Apovincaminate and Xanthinol Nicotinate in cerebrovascular diseases” Arzneim Forsch (drug research) 28. Tretter L.20(5):435-43. J Int Medical Res 1992 Sep. Vamosi. Nihon Bioresearch Center Inc. J Neurophysiol 1996 Feb.

You're Reading a Free Preview

/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->